Skip to main content

Table 3 Determinants of antipsychotic prescribing using multivariate logistic GEE estimation (N = 199,549)

From: Antipsychotic prescribing for Alzheimer’s disease and related disorders in specialized settings from 2010 to 2014 in France: a repeated cross-sectional study

 

Adjusted odds ratio

95% confidence interval

p value

Year

 2010

1

  

 2011

1.10

1.05–1.15

<0.001

 2012

1.12

1.06–1.17

<0.001

 2013

1.16

1.10–1.21

<0.001

 2014

1.23

1.17–1.30

<0.001

MMSE

 0–10

2.63

2.51–2.75

<0.001

 11–20

1.56

1.51–1.62

<0.001

 21–30

1

  

Age at first consultation with the diagnosis

 ≤75 years

1

  

 76–80 years

0.91

0.86–0.96

0.001

 81–85 years

0.85

0.81–0.90

<0.001

 >85 years

0.80

0.76–0.84

<0.001

Gender

 Female

1

  

 Male

1.34

1.30–1.39

<0.001

Education (years)

 0

1

  

 1–5

0.87

0.82–0.92

<0.001

 6–12

0.84

0.78–0.89

<0.001

 ≥13

0.77

0.70–0.84

<0.001

 Unknown

0.96

0.89–1.03

0.224

Type of centre

 Memory clinic

1

  

 Regional reference memory centre

0.83

0.77–0.91

<0.001

 Private practice neurologist

0.60

0.42–0.86

0.006

Antidepressant

 No

1

  

 Yes

1.77

1.71–1.84

<0.001

Hypnotic

 No

1

  

 Yes

1.91

1.82–2.01

<0.001

Anxiolytic

 No

1

  

 Yes

2.42

2.33–2.51

<0.001

NMDA antagonist

 No

1

  

 Yes

1.32

1.28–1.36

<0.001

Lifestyle

 Community-living

1

  

 Long-term care facility

2.01

1.94–2.09

<0.001

Patient's location

 Within 50 km from memory consultation

1

  

 >50 km from memory consultation

0.93

0.87–1.00

0.036

Years × type of centera

  

<0.001

  1. GEE generalized estimating equations, MMSE Mini Mental state examination, NMDA N-methyl-D-aspartate receptor
  2. aSignificant interaction entered in the model